SEC Form 4 · accession 0001562180-17-001461
ARRAY BIOPHARMA INC · ARRY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Kyle Lefkoff
Director
Period of report
Mar 31, 2017
Accepted (ET)
Apr 4, 2017 · 9:41 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001100412
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 28, 2016 | G | 2,000 | $0.00 | D | 6,585 | D | |
| Common Stock | Mar 31, 2017 | M | 25,000 | $3.69 | A | 31,585 | D | |
| Common Stock | Mar 31, 2017 | M | 20,000 | $4.36 | A | 51,585 | D | |
| Common StockF1 | Mar 31, 2017 | S | 45,000 | $8.92 | D | 6,585 | D | |
| Common StockF2 | holding | — | — | — | 45,000 | I | See footnote |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF3 | $3.69 | Mar 31, 2017 | M | 25,000 | D | — | Apr 25, 2022 | Common Stock | 25,000 | 0 | D |
| Stock Option | $4.36 | Mar 31, 2017 | M | 20,000 | D | Oct 24, 2013 | Oct 24, 2022 | Common Stock | 20,000 | 0 | D |
Explanation of responses
- F1The price reported for these shares is the weighted average sale price. Details of actual prices for shares sold are available from the Issuer upon request.
- F2Comprised of 30,000 shares of common stock in trust for the benefit of Mr. Lefkoff's minor children and 15,000 shares of common stock held by BV Partners III Profit Sharing account for the benefit of Mr. Lefkoff.
- F3The option vested in 2 equal annual installments beginning on April 25, 2013.